ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1820

Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Gardasil®) and Autoimmune Disorders: Safety Assessment Using the Pharmacoepidemiologic General Research Extension System

Lamiae Grimaldi-Bensouda1, Michel Rossignol2, Elodie Aubrun1, Pamela Leighton3, Didier Guillemot4, Alfred Mahr5, Jacques Benichou6, Paul-Henri Lambert7, Bertrand Godeau8 and Lucien Abenhaim9, 1LA-SER, Paris, France, 2LA-SER, Centre for Risk Research, Montreal, Canada, 3LA-SER Europe Ltd., London, United Kingdom, 4Institut Pasteur (PhEMI)/ INSERM U657 & Université Paris-Ile de France Ouest, Paris, France, 5Internal Medicine, Hospital Saint-Louis, Paris, France, 6INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, Rouen, France, 7Centre of Vaccinology & neonatal immunology, University of Geneva, Geneva, Switzerland, 8Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, 9LA-SER Europe Ltd, London, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoimmune diseases, human papillomavirus (HPV) and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: This study investigated whether the human papillomavirus (HPV) vaccine [types 6, 11, 16, 18] is associated with a modified risk of autoimmune disorders (AIDs). It carried out a case-control study within the population targeted for HPV vaccination.

Methods: The following AIDs were studied: central demyelination, Guillain-Barré syndrome, connective tissue disorders (lupus, rheumatoid arthritis, myositis, dermatomyositis, undifferentiated connective tissue disorder), type 1 diabetes, autoimmune thyroid disorders (Graves’ disease, Hashimoto’s thyroiditis) and immune thrombocytopenia. A network of specialist centers (internal medicine, neurology, rheumatology, paediatrics, endocrinology, dermatology) throughout France recruited newly-diagnosed cases in females 14 – 26 years-old. Cases were diagnosed according to standardized criteria. Controls were recruited from general practice settings and matched to cases on age (within ± one, ± three, ± six or ± 12 months successively if no match was found for cases under 18 years-old, within ± 12 or ± 24 months for cases 18 years-old or older), region of residence (northern or southern France) and recruitment consultation date (within ± three or ± nine months). Vaccinations and other potential risk factors for AIDs were assessed in a standardized telephone interview of patients or their parents. The interviewers were blind to case/control status.

Results: Between December 2007 and April 2011, 113 specialist centers recruited 248 definite cases of AIDs which were matched to 1001 controls. 97.4% of reported vaccinations against HPV [types 6, 11, 16, 18] were confirmed using medical records from the patients or their general practitioners. A smaller proportion of cases (26 or 10.5%) than controls (232 or 23.2%) received the HPV vaccine [types 6, 11, 16, 18] within predefined time windows up to 24 months before the index date but the difference was not statistically significant (adjusted odds ratio 0.72, 95% confidence interval 0.45, 1.18). No association was found when each AID was considered separately, although these analyses were based on small numbers of cases, or when considering various time windows prior to the index date, the inclusion of uncertain exposures to vaccination and unconfirmed cases. The specialist centers reported no important increase in incidence for any of the AIDs in the population eligible for HPV vaccination.

Conclusion: No evidence of an increased risk of the studied AIDs was observable following vaccination with HPV vaccine [types 6, 11, 16, 18] for the time window of study available.  The study lacked the power to conclude on individual disorders taken separately. The study observed no unusual accrual, in a large series of centers specialized in AIDs, of incident cases of any of the diseases surveyed in young females, at a time when one-third of them were getting vaccinated against HPV, mainly by HPV vaccine types 6, 11, 16, 18.


Disclosure:

L. Grimaldi-Bensouda,
None;

M. Rossignol,
None;

E. Aubrun,
None;

P. Leighton,
None;

D. Guillemot,

SPMSD,

5;

A. Mahr,

SPMSD,

5;

J. Benichou,
None;

P. H. Lambert,

SPMSD,

5;

B. Godeau,

SPMSD,

5;

L. Abenhaim,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/human-papillomavirus-vaccine-types-6-11-16-18-gardasil-and-autoimmune-disorders-safety-assessment-using-the-pharmacoepidemiologic-general-research-extension-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology